Literature DB >> 1804807

Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.

B G Durie1, J Crowley, C A Coltman, R A Chapman, S P Balcerzk, J D Bonnet, D A Lipschitz, R L Stephens, B D Cheson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1804807     DOI： 10.1007/BF00183574

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  8 in total

1.  Phase II trial of bisantrene in patients with metastatic melanoma.

Authors:  C Mackel; F L Meyskens; D S Alberts
Journal:  Cancer Treat Rep       Date:  1986-08

Review 2.  Staging and kinetics of multiple myeloma.

Authors:  B G Durie
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

3.  Bisantrene, an active new drug in the treatment of metastatic breast cancer.

Authors:  H Y Yap; B S Yap; G R Blumenschein; B C Barnes; F C Schell; G P Bodey
Journal:  Cancer Res       Date:  1983-03       Impact factor: 12.701

4.  Direct cloning of human malignant melanoma.

Authors:  D D Von Hoff; B Forseth; H R Metelmann; G Harris; S Rowan; C A Coltman
Journal:  Cancer       Date:  1982-08-15       Impact factor: 6.860

5.  Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.

Authors:  B G Durie; D O Dixon; S Carter; R Stephens; S Rivkin; J Bonnet; S E Salmon; L Dabich; J C Files; J J Costanzi
Journal:  J Clin Oncol       Date:  1986-08       Impact factor: 44.544

6.  Bisantrene, an active drug in patients with advanced breast cancer.

Authors:  C K Osborne; D D Von Hoff; J D Cowan; J Sandbach
Journal:  Cancer Treat Rep       Date:  1984-02

7.  Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.

Authors:  B G Durie; L A Young; S E Salmon
Journal:  Blood       Date:  1983-05       Impact factor: 22.113

8.  New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.

Authors:  S E Salmon; F L Meyskens; D S Alberts; B Soehnlen; L Young
Journal:  Cancer Treat Rep       Date:  1981 Jan-Feb
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.